📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. (2022)

First Author: ACTIV-3/Therapeutics For Inpatients With COVID-19 (TICO) Study Group

Attributed to: Respiratory infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(21)00751-9

PubMed Identifier: 34953520

Publication URI: http://europepmc.org/abstract/MED/34953520

Type: Journal Article/Review

Volume: 22

Parent Publication: The Lancet. Infectious diseases

Issue: 5

ISSN: 1473-3099